Importance of allogeneic stem cell transplantation in myelofibrosis

Summary Allogeneic stem cell transplantation (alloSCT) is the only curative treatment option for patients with high-risk myelofibrosis (MF). However, it is important to bear in mind that alloSCT in MF is associated with a nonrelapse mortality that should not be underestimated. Therefore, both exact disease risk categorization and thorough evaluation of the individual transplant-related risk are mandatory to identify those patients to whom alloSCT should be offered. This short review is intended to provide a concise overview on relevant aspects to be considered for patient selection, planning, and performing alloSCT.